Maximizing human epidermal growth factor receptor 2 inhibition: A new oncologic paradigm in the era of targeted therapy

Journal of Clinical Oncology

Volumn 30, Issue 14, 2012, Pages 1712-1714

  Olson, Erin M ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; HETERODIMER; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL DEATH; CELL SURVIVAL; CLINICAL PRACTICE; DISEASE CONTROL; DISEASE COURSE; DRUG EFFICACY; HUMAN; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; PATHOGENESIS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; SHORT SURVEY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE; BREAST TUMOR; FEMALE; METABOLISM; NOTE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTOR, ERBB-2;

EID: 84863752698     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.2545     Document Type: Short Survey

References (26)

1. Blackwell KL, Burstein HJ, Storniolo AM, et al: Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2- positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124-1130, 2010
2. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
3. von Minckwitz G, du Bois A, Schmidt M, et al: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 27: 1999-2006, 2009
4. Dawood S, Broglio K, Buzdar AU, et al: Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review. J Clin Oncol 28:92-98, 2010
5. Baselga J, Gelmon KA, Verma S, et al: Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28: 1138-1144, 2010
6. Cortés J, Fumoleau P, Bianchi GV, et al: Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: Activitiy and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30:1594-1600, 2012
7. Yarden Y, Sliwkowski M: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137, 2001
8. Garrett TP, McKern NM, Lou M, et al: The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 11:495-505, 2003
9. Baselga J, Swain SM: Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9:463-475, 2009
10. Franklin MC, Carey KD, Vajdos FF, et al: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5:317-328, 2004
11. Krop I, LoRusso P, Miller K, et al: A phase II study of trastuzumab-DM1 (T-DM1), a novel HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer who were previously treated with an anthracycline, a taxane, capecitabine, lapatinib, and trastuzumab. Presented at the 35th European Society for Medical Oncology Congress, Milan, Italy, October 8-12, 2010
12. Burstein HJ, Sun Y, Dirix LY, et al: Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 28:1301-1307, 2010
13. Hickish T, Wheatley D, Lin N, et al: Use of BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor (TKI), to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab. J Clin Oncol 27:46s, 2009 (suppl 15; abstr 1023)
14. Liu P, Cheng H, Roberts TM, et al: Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8:627-644, 2009
15. Santen RJ, Song RX, McPherson R, et al: The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 80:239-256, 2002
16. Shi F, Telesco SE, Liu Y, et al: ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci U S A 107:7692-7697, 2010
17. Alimandi M, Romano A, Curia MC, et al: Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10:1813-1821, 1995
18. Hellyer NJ, Kim MS, Koland JG: Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor. J Biol Chem 276:42153-42161, 2001
19. Campbell MR, Amin D, Moasser MM: HER3 comes of age: New insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res 16:1373-1383, 2010
20. Ghosh R, Narasanna A, Wang SE, et al: Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res 71: 1871-1882, 2011
21. Tortora G: Mechanisms of resistance to HER2 target therapy. J Natl Cancer Inst Monogr 2011:95- 98, 2011
22. Cho HS, Mason K, Ramyar KX, et al: Structure of the extracellular region of HER2 alone and in complex with the Herceptin fab. Nature 421:756-760, 2003
23. Olson EM, Lin NU, Dipiro PJ, et al: Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2- positive metastatic breast cancer. Ann Oncol 23:93- 97, 2012
24. Baselga J, Cortés J, Kim S, et al: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med [epub ahead of print on December 7, 2011]
25. Olson EM, Lin NU, Krop IE, et al: The ethical use of mandatory research biopsies. Nat Rev Clin Oncol 8:620-625, 2011
26. Wagle N, Emery C, Berger MF, et al: Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29:3085-3096, 2011